Title: Biomarkers as Key Drivers of Drug Development in Gene Therapy

Biography:

Executive veteran of the biopharmaceutical industry with extensive global leadership experience in translational science, clinical development and global medical affairs.C-suite executive and industry leader providing in-depth expertise for pre-clinical and clinical study strategy, planning, execution and monitoring, regulatory interactions, investor relations, fundraising, M&A and IPO process and deliverables.  Chief Medical Officer for ASC Therapeutics, former CMO for Symvivo, Myriad Genetics and CellMax Life, Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie (Humira).

Abstract

Biomarkers are tools that can facilitate selection and monitoring of gene therapies, and their proper identification and application allows patients to be treated accurately, effectively, and safely. Several biomarkers of disease, immune, cellular, and molecular responses to gene therapies are available, and the role of biomarkers will expand as gene therapies continue to develop. Selecting the right patient for the right therapy and monitoring that patient’s response to the therapy is imperative for drug discovery. With the rapid growth of gene therapies, biotechnology and pharmaceutical companies face a call to action: We must establish proper selection and monitoring protocols to provide patients with the safest and most effective therapeutic options for genetic diseases. Precision medicine is changing the way we think about, prevent, treat, and monitor many diseases.